Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10454189 | 0.96 | LMNA (0.57) | LMNACYP2C19HIF1A | |
| SCHEMBL13885052 | 0.95 | LMNA (0.58) | LMNACYP2C19HIF1AMAP2K2MAP2K1 | |
| SCHEMBL3758885 | 0.94 | LMNA (0.55) | LMNACYP2C19HIF1A | |
| SCHEMBL3744891 | 0.94 | LMNA (0.67) | LMNACYP2C19HIF1A | |
| SCHEMBL13180644 | 0.93 | LMNA (0.55) | LMNACYP2C19HIF1A | |
| SCHEMBL3665690 | 0.92 | LMNA (0.51) | LMNACYP2C19HIF1A | |
| SCHEMBL3663722 | 0.92 | LMNA (0.63) | LMNACYP2C19HIF1AMAP2K2MAP2K1 | |
| SCHEMBL13885418 | 0.92 | LMNA (0.55) | LMNACYP2C19HIF1AMAP2K2MAP2K1 | |
| SCHEMBL9189525 | 0.92 | LMNA (0.60) | LMNACYP2C19HIF1AMAP2K2MAP2K1 | |
| SCHEMBL13247531 | 0.91 | LMNA (0.61) | LMNACYP2C19HIF1AMAP2K2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | claimed |
| EP-2231200-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-09-29 | — | — | EP | claimed |
| WO-2009071605-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-06-11 | — | — | WO | claimed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| WO-2009071605-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303734-A1 | CONTRAST AGENTS | C1R, CNKSR1, C5 | LMNA 2025/4885CYP2C19 2823/4885HIF1A 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.